Advising Healthcare & Life Sciences Businesses
Transactions in healthcare and life sciences take place within strict regulatory frameworks, where licensing status and supervisory approval can determine feasibility from the outset.
Valuation often depends on the stage of product development and the durability of intellectual property protection rather than on current earnings alone. In biopharma and biotech, clinical pipeline progress and data integrity can influence timing and structure, while in healthcare services and medtech, reimbursement arrangements and accreditation status may affect buyer appetite.
The healthcare market is strongly driven by technology and changing parameters such as demographics, budgeting, pandemic or patient empowerment, leading to consolidation, buy and build and technology-led transactions. This pattern creates a wide range of M&A market stakeholders, from owners and managers of small scale-ups to mid-sized enterprises and large multinational firms.
CDI Global advises on acquisitions and divestitures across this diversity of healthcare and life sciences businesses, including proprietary search where appropriate. Each engagement is conducted with a clear understanding of regulatory sequencing and completion requirements.
Healthcare & Life Sciences Sector Overview
The Healthcare & Life Sciences sector is an economic ecosystem that provides medical products and services to patients. These can include preventive services, curative treatments, preventive care, rehabilitation services and palliative care. Modern healthcare consists of four main segments:
- Healthcare Providers & Services: Hospitals, doctors, nursing homes, diagnostic labs
- Pharmaceuticals & Biotechnology: Companies that develop, produce, and market drugs, nutraceuticals and medications
- Medical Devices & Technology: Manufacturers of equipment, consumables, devices, software, ranging from bandages to MRI machines
- Healthcare Finance & Payers: Insurance companies and government entities
The sector includes businesses at very different stages of development, from early research platforms to established providers with recurring income: In life sciences transactions, value often depends on the strength of the clinical pipeline, quality of trial data, and duration of patent protection, as a single product can represent a significant proportion of the overall value. In healthcare services and medtech, revenue stability is closely linked to reimbursement frameworks and accreditation status, and buyers assess how income is generated and how exposed the business is to pricing pressure or policy change.
Our Experience in Healthcare & Life Sciences
CDI Global has advised healthcare and life sciences businesses and financial investors on acquisitions and divestitures within regulated markets. Many assignments involve privately owned companies, where ownership transitions must align with regulatory notifications and licence continuity.
Much of our work involves proprietary search, particularly where innovative businesses are not publicly marketed and direct engagement with founders or scientific leadership is required. Discussions are handled carefully to protect sensitive clinical data and intellectual property.
Transactions often require understanding the technology and application, and clear sequencing of approval steps before completion. Transaction structures may include staged consideration tied to defined milestones, with senior partners directly involved throughout negotiations and closing.
CDI Global relies on a dedicated group of more than 15 Healthcare and Life Sciences industry experts to advise and support clients throughout these industry-specific M&A processes.
